Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing.
Looking for a particular Poseida Therapeutics, Inc. employee's phone or email?
Poseida Therapeutics, Inc. Questions
The Poseida Therapeutics, Inc. annual revenue was $88.5 million in 2026.
Johanna Mylet is the CFO of Poseida Therapeutics, Inc..
217 people are employed at Poseida Therapeutics, Inc..
Poseida Therapeutics, Inc. is based in San Diego, California.
The NAICS codes for Poseida Therapeutics, Inc. are [54, 5417, 54171, 541714, 541].
The SIC codes for Poseida Therapeutics, Inc. are [873, 87].
Top Poseida Therapeutics, Inc. Employees
-
Johanna Mylet
Chief Financial Officer at Poseida Therapeutics, Inc.
San Diego, CA, US14 -
Loren Wagner
Chief Operations Officer at Poseida Therapeutics, Inc.
San Diego, CA, US22 -
24
-
25+
-
21
Related Companies
